Allison Dorval - Feb 14, 2024 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: Chief Financial Officer
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval
Stock symbol: VERV
Transactions as of: Feb 14, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/16/2024, 04:30 PM
Previous filing: Dec 1, 2023
Next filing: Jun 7, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Award	$0	+180K		$0.00	180K	Feb 14, 2024	Common Stock	180K	$12.75	Direct	F1
transaction	VERV	Restricted Stock Units	Award	$0	+45K		$0.00	45K	Feb 14, 2024	Common Stock	45K		Direct	F2, F3

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.